Clinical trial
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III Trial)
NCT05363761 is registered in ClinicalTrials.gov with Neurotronic, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III Trial)
- Lead sponsor
- Neurotronic, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 19, 2022
- Completion date
- January 31, 2029
- Enrollment
- 50 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.